🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
Evaluate the proportion of patients with an urticaria control test \[UCT\] ...
Status
Completed
Location
Novartis Investigative Site
Start Date
2015-04-22
Trial ID
NCT02550106
Treatments Being Tested
The first phase of this study will be a parallel, 12-week treatment, Phase ...
Status
Completed
Location
Investigational Site Number : 0320006
Start Date
2021-11-24
Trial ID
NCT05107115
Treatments Being Tested
The purpose of this study is to evaluate sacituzumab tirumotecan versus pem...
Status
Active Not Recruiting
Location
Kaiser Permanente - Oakland ( Site 0054)
Start Date
2024-06-11
Trial ID
NCT06305754
The study is a Phase II, dose-ranging, multicenter, randomized, double-blin...
Status
Completed
Location
Multiple Locations
Start Date
2009-03
Trial ID
NCT00866788
Treatments Being Tested
The purpose of this study was to evaluate the safety, tolerability and effi...
Status
Completed
Location
Novartis Investigative Site
Start Date
2022-01-15
Trial ID
NCT05048342
Treatments Being Tested
The study is designed to explore the mode of action for omalizumab therapy ...
Status
Completed
Location
Novartis Investigative Site
Start Date
2012-04
Trial ID
NCT01599637
The main goals are after treatment given before surgery, to measure the num...
Status
Recruiting
Location
Southern Cancer Center (SCC) ( Site 8004)
Start Date
2025-03-20
Trial ID
NCT06788912
The study is a global Phase III, multicenter, randomized, double-blind, pla...
Status
Completed
Location
Multiple Locations
Start Date
2011-02
Trial ID
NCT01264939
Patients with HBeAG positive, chronic HBV infection will receive either ARC...
Status
Terminated
Location
Research Site 1
Start Date
2015-11
Trial ID
NCT02604212
Treatments Being Tested
This was a multicenter, randomized, double-blind and placebo-controlled pha...
Status
Completed
Location
Novartis Investigative Site
Start Date
2019-06-06
Trial ID
NCT03926611
Treatments Being Tested